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Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is conventionally considered a critical enzyme that involves
in glycolysis for energy production. Recent previous studies have suggested that GAPDH is important in
glutamate-induced neuronal excitotoxicity, while accumulated evidence also demonstrated that GAPDH nuclear
translocation plays a critical role in cell death. However, the molecular mechanisms underlying this process remain
largely unknown. In this study, we showed that GAPDH translocates to the nucleus in a Siah1-dependent manner upon
glutamate stimulation. The nuclear GAPDH forms a protein complex with p53 and enhances p53 expression and
phosphorylation. Disruption of the GAPDH-p53 interaction with an interfering peptide blocks glutamate-induced
cell death and GAPDH-mediated up-regulation of p53 expression and phosphorylation. Furthermore, administration of
the interfering peptide in vivo protects against ischemia-induced cell death in rats subjected to tMCAo. Our data
suggest that the nuclear p53-GAPDH complex is important in regulating glutamate-mediated neuronal death and
could serve as a potential therapeutic target for ischemic stroke treatment.Introduction
GAPDH is traditionally thought to be a critical enzyme
for glycolysis, and therefore, an important protein in en-
ergy production. However, recent evidence suggests that
GAPDH is also involved in apoptosis, as indicated by
changes in GAPDH expression and subcellular localization
during apoptosis [1-4]. Indeed, GAPDH is not restricted
to the cytosol, but it is also found in the nucleus,
plasma membrane and extracellular space. The subcel-
lular localization of GAPDH may be important for the
multifuntional role of GAPDH.
Membrane-associated GAPDH binds to tubulin, thereby
regulating polymerization and bundling of microtubules
near the cell membrane. This suggests that GAPDH is
involved in the organization of subcellular organelles
[5]. Furthermore, release of tubulin from membrane-
associated GAPDH facilitates the fusion of vesicles to
the plasma membrane [6]. Interestingly, GAPDH can
also be secreted from cells, where it can associate with* Correspondence: f.liu.a@utoronto.ca
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unless otherwise stated.the cell surface and inhibit cell spreading [7]. Yamaji
et al. reported that GAPDH is detected in conditioned
medium of cultured cell lines such as Cos-7, HEK-293
and neuro-2a, as well as rat serum [7]. In the cytosol,
RNA/GAPDH interactions enable GAPDH to regulate
protein translation by controlling the rate of protein
synthesis and altering the stability of mRNA [8,9]. Fur-
thermore, GAPDH is essential for ER to Golgi transport
through interactions with Rab2 GTPase and atypical
protein kinase C ℓ/λ (aPKCℓ/λ), both involved in the
early secretary pathway and vesicle formation [10-12].
In the nucleus, GAPDH acts as a DNA binding protein
and a t-RNA transport protein, and is important for the
transportation and maintenance of nucleic acid [13,14].
The uracil DNA glycosylase activity of GAPDH, together
with its ability to bind to diadenosine tetraphosphate,
implies that GAPDH is involved in DNA replication
and repair [15].
Recently, accumulated evidence has suggested that
GAPDH nuclear translocation is associated with cell
toxicity triggered by various agents, including glutamate
[16]. Furthermore, the S-nitrosylation of GAPDH upon
nitric oxide (NO) stimulation can trigger the nuclear. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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GOSPEL [17], AIRE [18], SIRT1 [19], Mitochondrial un-
coupling protein 2 (UCP2) [20] and CIB1 [21] can promote
or suppress the nuclear translocation of GAPDH in various
cell types. However, the mechanism by which GAPDH ac-
tivates the cell death pathway in the nucleus remains
largely unknown, despite several studies have suggested the
involvement of p53, a cellular tumor suppresser [22,23].
In the present study, we hypothesize that GAPDH
translocates to nucleus upon glutamate stimulation. Sub-
sequently, nuclear GAPDH forms a complex with p53
that leads to the activation of p53-mediated cell death
pathway. Finally, we also hypothesize that GAPDH nu-
clear translocation plays a role in ischemic stroke, and




The peptides were synthesized by Biomatik Corporation
(Cambridge, USA). To facilitate the intracellular delivery
of the peptide, both the GAPDH2–2–1–1 peptide and
scrambled GAPDH2–2–1–1 peptide were fused to the cell
membrane transduction domain of the HIV-1 TAT protein
[YGRKKRRQRRR [24]] as previously described [25]. We
refer to them here as: TAT-GAPDH2–2–1–1 and TAT -GA
PDH2–2–1–1-SCRM. The amino acid sequence for the TAT-
GAPDH2–2–1–1 peptide was YGRKKRRQRRRIPELNGKLT
GMAFRVPTANV, and for TAT-GAPDH2–2–1–1-SCRM, YG
RKKRRQRRRVGNTALTKPGVNRLFEAPMI. The peptide
was purified by HPLC to at least 90% purity. The peptide
was dissolved in saline, aliquoted prior to use, and stored
at −80°C.
GST fusion proteins and mini-genes
The GST fusion protein and mini-genes are made as pre-
viously described [26-29]. Briefly, cDNA fragments were
amplified by using PCR with specific primers to construct
GST-fusion proteins and mini-genes encoding truncated
GAPDH. Except where specified, all 5’ and 3’ oligonucleo-
tides incorporated BamH1 (GGATCC) and Xho1 sites
(CTCGAG), respectively, to facilitate sub-cloning into the
pcDNA3 vector (for mini-gene construction) or into
pGEX-4 T3 vector (for GST-fusion protein construction).
GST-fusion proteins were prepared from bacterial lysates
with glutathione sepharose 4B beads as described by the
manufacturer (Amersham). To confirm appropriate splice
fusion and the absence of spurious PCR-generated nucleo-
tide errors, all constructs were re-sequenced.
Protein affinity purification, co-immunoprecipitation and
western blots
Protein affinity purification, co-immunoprecipitation and
Western blot analyses were performed as previouslydescribed [29-31]. For affinity purification experiments,
solubilized tissue extracts (800 μg protein) were incubated
with glutathione-sepharose beads (GE Healthcare) bound
to the indicated GST-fusion proteins (50 μg) at room
temperature for 1 hour. Beads were washed, boiled for
5 min in SDS sample buffer and subjected to SDS-PAGE.
After transfer of proteins onto nitrocellulose, membranes
were Western blotted with the antibody of interest. For
co-immunoprecipitation, briefly, solubilized tissue extracts
(800 μg of protein) were incubated with protein A/G agar-
ose for 4 hours at 4°C, followed by the addition of 20ul of
protein A/G agarose (Santa Cruz Biotechnology) and p53
(polyclonal, Abcam, 2 μg) for 12 hours. Pellets were
washed, boiled for 5 min in SDS sample buffer and sub-
jected to 10% SDS-PAGE. 50 μg of striatal tissue ex-
tracted protein was used as control in each experiment.
For Western blot, protein extracts were subject to 10%
SDS-PAGE. After electrophoresis, protein was trans-
ferred to nitrocellulose membrane and blocked using
5% non-fat milk, followed by antibody incubation over-
night. After rinsing the membrane for 5 min × 6 times,
blot was incubated with desired HRP conjugated sec-
ondary antibody (1:5,000-1:10,000) for 2 h and the blot
is incubated with Clarity Western ECL Substrate (Bio-rad)
and developed in the ChemiDoc MP system (Bio-rad).
The following antibodies were used for immunoprecipita-
tion and Western blots: GAPDH (polyclonal from Abcam,
1:1000; monoclonal from Chemicon, 1:500), α-tubulin
(monoclonal, Sigma-Aldrich, 1:10000), Siah1 (polyclonal
from Abcam, 1:1000) and LaminB1 (Zymed Laboratories,
1:1000), p53 (immunoprecipitation, polyclonal, Abcam,
1000; western blotting, monoclonal, Abcam, 1:1000).
Quantification of AMPAR-mediated excitotoxicity
HEK-293 T cells transfected with GluR1/2 subunits were
exposed to 300 μM glutamate/25 μM cyclothiazide at 37°C
for 24 hour. Cells were allowed to recover for 24 hours at
37°C. To quantify AMPAR-mediated cell death, the culture
medium was replaced by a solution containing 50 μg/ml
propidium iodide (PI) (Invitrogen, Carlsbad, CA). After
30 minute incubation at 37°C, fluorescence intensity in
each well was measured with a plate reader (Victor3; Perki-
nElmer, Waltham, MA). The fraction of dead cells was
normalized to the cell toxicity that occurred in either the
glutamate-treated cells or KA-treated neurons. Primary
cortical neurons were exposed to 100 μM KA/25 μM
cyclothiazide in the presence of NMDAR and Ca2+ channel
antagonists (10 μM MK-801 and 2 μM nimodipine, re-
spectively) at 37°C for 1 hour.
Transient middle cerebral artery occlusion (tMCAo) methods
All animals were purchased from Charles River Laboratories,
Wilmington, MA. All animal procedures were approved by
the Animal Care Committee of Center for Addiction and
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and regulations of the Canadian Council on Animal Care.
Sprague Dawley rats weighing from 300 g-325 g (~7-8 weeks)
were used for tMCAo modeling. Transient focal cere-
bral ischemia (90 minutes) was induced by right intra-
luminal middle cerebral artery occlusion (MCAo) as
described previously [25,32]. Briefly, rats were anesthe-
tized using 2.5% isoflurane supplemented with 97.5%
compressed air. tMCAo was achieved by introducing a
3–0 monofilament suture into the middle cerebral ar-
tery via the internal carotid artery. During ischemia,
body temperature was maintained at 36.5-37.5°C with a
rectal feedback controlled homeothermic blanket sys-
tem and a heating lamp [25]. 24 hours after tMCAo on-
set, rats were deeply anesthetized and sacrificed. The
brains were cut into 1-mm-thick coronal sections and
stained with 0.05% 2, 3, 5-triphenyltetrazolium chloride
for 30 minutes at 37°C, followed by overnight immersion
in 10% formalin. The infarct zone was demarcated and an-
alyzed using Image J software. 2 hours after tMCAo and
10 minutes before the animals were killed, two neuro-
logical tests were performed [33]. The postural reflex test
was used to examine upper body posture [34] while the
forelimb placing test was used for sensorimotor integra-
tion in forelimb response to visual, tactile, and propriocep-
tive stimuli [35]. Performance on these tests was used to
grade neurological function on a scale of 0–12 (0, normal;
12, worst). In the treatment groups, a single injection of
4 μl 10 mM TAT-GAPDH2–2–1–1 or TAT-GAPDH2–2–1–1
Scrambled peptide was infused intracerebroventricularly
(i.c.v.) (AP: −1.0 mm; LM: −1.4 mm; DV: −3.6 mm from
Dura) 30 minutes after the onset of tMCAo, whereas the
sham operation group underwent all the surgical proce-
dures except for the insertion of a suture.
Intracerebroventricular (ICV) peptide delivery
30 min after the termination of MCAo suture insertion,
peptide was delivered into the brain to investigate the
treatment effect. ICV procedure was performed as previ-
ously described [36]. Rats were anesthetized with 3% iso-
flurane and placed in a stereotaxic apparatus (David
Kopf Instrument, Tujunga, USA). The top of the skull
was shaved and swabbed with an antiseptic, then a mid-
line frontal incision was made in the scalp and the skin
was retracted bilaterally. Burr holes (2 mm) were drilled
into the skull and injecting needles were inserted at the
following coordinate: 0.8 mm posterior to the bregma,
1.5 mm lateral to the midline, and 4.5 mm ventral to the
surface of the skull. Rats received 4 μl infusions of either
TAT-GAPDH2–2–1–1 or TAT-GAPDH2–2–1–1-SCRM at a
rate of 0.35 μl min−1 into the lateral cerebral ventricular.
The injection cannula was left in place for 1 min follow-
ing the infusion. Afterwards, the needle was slowly
moved out and bone wax was applied to block the hole.Then the skull muscle and skin were stitched and rats
were placed back to the cage to recover.
Tetrazolium chloride (TTC) staining and infarct area
measurement
TTC staining was performed as previously described with
some modifications [36]. Briefly, 24 hours, 3 days and
5 days after tMCAO onset, rats were deeply anesthetized
and decapitated. The brains were dissected and cut into 1-
mm-thick coronal sections and stained with 0.25% 2, 3, 5-
triphenyltetrazolium chloride for 15–25 minutes at 37°C,
followed by overnight immersion in 4% formalin. The in-
farct zone was demarcated and analyzed with Image J soft-
ware (Bethesda, MD). Edema is adjusted and normalized
to the contralateral hemisphere of the same slices.
Fluoro-jade B staining
Fluoro-Jade B staining was performed as previously de-
scribed [36]. Animal used here is a new set of animals
that is different from the ones used in TTC staining.
Briefly, frozen sections (25 μm) of rat brains were used.
Tissue slices were first immersed in 1% sodium hydrox-
ide in 80% alcohol for 5 min, followed by 2 min in 70%
alcohol and 2 min in distilled water. The slides were
then transferred to a solution of 0.06% potassium per-
manganate for 10 min. After rinsing by distilled water for
2 min, the slices were stained in 0.0004% of the staining so-
lution. Then the slices were rinsed and mounted for con-
focal microscopy. An unbiased stereological analysis was
used to count the Fluoro-Jade B-labeled (FJ+) neurons in
the layer 3 of the cortex [37]. The brain region sectioned
for the Fluoro-Jade B staining is around the injection site
(approximately ±2 mm Bregma of the injections site). In
this region, the effect of the treatment is expected to be
maximized due to the higher concentration of the TAT-
GAPDH2–2–1–1 peptide.
Statistical Analysis
All data presented here are presented as Mean ± SEM
unless otherwise stated. Data are analyzed by either un-
paired t test or one way ANOVA as stated. Statistical
difference was considered significant if P < 0.05.
Results
Glutamate induces GAPDH nuclear translocation in a
Siah1-dependent manner
Previous studies have demonstrated that glutamate stimula-
tion promotes GAPDH nuclear translocation, which leads
to the activation of the cell death pathway [4]. Thus, we
first confirmed whether GAPDH was translocated to the
nucleus after agonist stimulation of AMPA receptors. We
focused on AMPA receptors due to the tight association
between AMPA receptor-mediated toxicity and ischemic
neuronal death [38,39]. Consistent with previous
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cantly increased following the activation of AMPA re-
ceptor in HEK-293 T cells expressing GluR1/2 subunits,
and in rat primary cultured neurons from the hippo-
campus and cortex (Figure 1A). LaminB1 was used as the
nuclear marker. There was no significant difference in the
total expression of GAPDH between the control group
and agonist stimulation group (Figure 1B).
Sequence analysis of GAPDH revealed no typical nuclear
localization signal (NLS). Previous studies have suggested
that GAPDH translocates to nucleus through coupling
with Siah1 [4,40], an E3 ubiquitin ligase with a NLS se-
quence [41]. Thus we tested whether Siah-1 is required for
glutamate-mediated nuclear translocation of GAPDH by
knocking down the expression of Siah 1 with siRNA (Santa
Cruz Biotechnology). As shown in Figure 2A-B, Siah1
siRNA significantly inhibited glutamate-induced nuclear
translocation of GAPDH. The Siah1 siRNA was highlyA
-tubulin
GAPDH













Figure 1 The nuclear translocation of GAPDH is increased upon
KA or glutamate treatment in neurons and GluR1/2 transfected
HEK 293 T cells. A. Representative lot of Western blot analysis of
nuclear (right) and cytosol extract (left) using antibodies against GAPDH
or α-tubulin in neurons or HEK 293 T cells upon KA or glutamate
stimulation. B. Representative blot of Western blot analysis of total
protein expression of GAPDH and α-tubulin in neurons or HEK
293 T cells upon KA or glutamate stimulation. All Western blot
analysis was repeated for at least three times.effective in knocking-down the expression of Siah1, as
shown in Figure 2C. To exclude off-target effects of the
Siah1 siRNA, we tested an additional three Siah1 siRNAs
and one scrambled negative control siRNA from ORI-
GENE (Figure 2D) for their ability to inhibit GAPDH nu-
clear translocation. Taken together, these data suggested
that GAPDH may translocate into the nucleus in a Siah1
dependent manner.
p53 forms a protein complex with GAPDH in the nucleus
Several recent studies have shown that nuclear GAPDH
forms a complex with p53 related protein [17,23]. p53, a
tumor suppressor and transcription factor, has been impli-
cated in glutamate-mediated excitotoxicity and ischemic
neuronal damage [42-44]. Therefore we tested whether
GAPDH forms a complex with p53 in the nucleus using
co-immunoprecipitation (CoIP). As shown in Figure 3A,
the p53 antibody was able to co-immunoprecipitate with
GAPDH from solubilized nuclear proteins extracted from
rat hippocampal slices. Interestingly, agonist stimulation fa-
cilitated p53-GAPDH complex formation, implicating that
this protein complex is likely to be involved in glutamate-
mediated function.
We then developed an interfering peptide that is able
to disrupt the GAPDH-p53 complex to investigate the
function of the p53-GAPDH interaction. We created the
interfering peptide by identifying the amino-acid se-
quence of GAPDH that interacts with p53, through a
series of affinity pull down experiments. Initially, we
confirmed the interaction between p53 and GAPDH
using a GST-fusion protein encoding GAPDH (GST-
GAPDH). As shown in Figure 3C, GST-GAPDH, but not
GST alone or GST-GluR2NT, can pull down p53 in rat hip-
pocampal nuclear extracts. Furthermore, GST-fusion pro-
teins encoding fragments of GAPDH were constructed
and used in affinity purification assays (Figure 3B).
We concluded that the GAPDH: I221-E250 fragment facili-
tated the interaction with p53, since GST-GAPDH2–2–1–1
(I221-E250) was able to pull down p53 from solubilized
nuclear protein extracts derived from rat hippocampus
(Figure 3C). To confirm the critical role of the I221-
E250 sequence in the GAPDH-p53 interaction, we
tested whether a peptide encoding the I221-E250 region
could block the GAPDH-p53 interaction using co-
immunoprecipitation. As shown in Figure 3D, the abil-
ity of GAPDH antibody to co-immunoprecipitate with
p53 was significantly blocked by pre-incubation with
the I221-E250 peptide, indicating the I221-E250 region is
essential in maintaining p53-GAPDH coupling.
p53-GAPDH interaction plays an important role in AMPA
receptor-mediated cell death
We hypothesized that translocation of GAPDH to the nu-
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Figure 2 The nuclear translocation of GAPDH upon GluR2 AMPA receptor activation depends on Siah-1. A. Western blots verification of
Siah 1 siRNA knockdown of the Siah-1 expression in HEK 293 T cells. B. Western blots analysis of GAPDH expression in the nucleus with/without
glutamate treatment in the presence/absence of the Siah1 siRNA (Santa Cruz) in HEK-293 T cells expressing GluR1/2 subunits. LaminB1 was used
as the nuclear marker. C & D, Quantification of nuclear expression of GAPDH with/without glutamate treatment in the presence/absence of the Siah1
siRNA (Santa Cruz), three Siah1 siRNA (#1, #2, #3, OriGene) and scrambled negative control siRNA (scramble, OriGene). *p < 0.05; significantly different
from control group (n = 3 per group). #p < 0.05; significantly different from glutamate group (n = 3 per group). ANOVA, followed by post-hoc SNK test.
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formation. To test this hypothesis, we first confirmed
whether p53 is involved in AMPA receptor-mediated exci-
totoxicity as previous reported [45]. As shown in Figure 4A,
pre-treatment with the p53 inhibitor PFT-α (pifithrin-α,
10 μM, 1 hour) significantly inhibited glutamate-induced
cell death in HEK-293 T cells expressing GluR1/2 subunits,
whereas this effect was not seen in HEK-293 T cells ex-
pressing GluR1/3 subunits (Figure 4B). This result suggests
that p53 may play a role in GluR2 containing AMPAR-
mediated cell death.
We then hypothesized that if the p53/GAPDH complex
is critical for AMPA receptor-mediated excitotoxicity, dis-
ruption of the p53-GAPDH interaction should inhibit
AMPA receptor-mediated cell death. In HEK-293 T cells
expressing GluR1/2, activation of AMPA receptor induces
cell death. Pre-incubation with GAPDH2–2–1–1 peptide that
disrupts the p53-GAPDH interaction inhibited AMPA
receptor-mediated cell death (Figure 4C). To facilitate the
intracellular delivery of the peptide, the GAPDH2–2–1–1
peptide was fused to the cell membrane transduction do-
main of the HIV-1 TAT protein [YGRKKRRQRRR [24]] to
generate TAT-GAPDH2–2–1–1, as previously described [25].
Furthermore, we tested whether the TAT-GAPDH2–2–1–1peptide would block the GAPDH nuclear transloca-
tion. As shown in Figure 4D, pre-incubation with
TAT-GAPDH2–2–1–1 blocked glutamate-induced GAPDH
nuclear translocation in HEK-293 T cells expressing
GluR1/2 subunits.
Previous studies demonstrated a strong correlation be-
tween p53 expression and excitotoxic neuronal death
[46-48], while other studies reported that phosphorylation
can regulate p53 activity [49-52]. Thus, we tested whether
AMPA receptor activation affected p53 expression or
phosphorylation. As shown in Figure 4E, activation of
AMPA receptors resulted in a 143 ± 16% (n = 3, p < 0.05)
increase in p53 expression and a 147 ± 6% (n = 3, p < 0.05)
increase in p53 phosphorylation in HEK-293 T cells
expressing GluR1/2 subunits. These effects were
blocked by the TAT-GAPDH2–2–1–1 peptide. Together,
these data suggest that the p53-GAPDH interaction
plays a critical role in AMPA receptor-mediated cell
death.
Disruption of the p53-GAPDH interaction protects against
brain damage from focal ischemia in the rat
Because AMPA receptor-mediated neurotoxicity has been











































Figure 3 Identification of GAPDH-p53 interaction fragment of GAPDH molecule. A, CoIP assay of GAPDH/p53 using solubilized nuclear
proteins extracted from rat hippocampal slices with/without glutamate treatment. B, Schematic representation of GST-fusion proteins encoding
truncated GAPDH segments (gray colored bars indicate the positive fragments). C, Western blots of cortical nuclear p53 after affinity precipitation
by different GST-GAPDH fragments (GST and GST-GAPDH, GST-GAPDH1 and GST-GAPDH2, GST- GAPDH2–1 and GST-GAPDH2–2, GAPDH2–2–1 and
GAPDH2–2–2, GAPDH2–2–1–1, GAPDH2–2–1–2 and GAPDH2–2–1–3) D, CoIP of nuclear p53 by GAPDH primary antibody in HEK-293 T cells co-expressing
GluR1/2 subunits with GAPDH2–2–1–1 peptide.
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complex might also play a role in ischemic brain damage.
If so, an interfering peptide that is able to disrupt the p53-
GAPDH interaction should reduce neuronal death follow-
ing ischemia in vivo. To test this hypothesis, rat tMCAo
modeling was achieved according to the schematictimeline shown by Figure 5A. An unbiased stereological
analysis described previously [36] was used to count the
FJ labeled neurons (FJ+) in the penumbra areas of the
cortex. The cortex of the ischemic penumbra area is
as previously defined [55-57]: from the edge of the


































































































PFT- : 10µMPFT- : 0µM



































































Figure 4 p53-GAPDH interaction involves in GluR2 AMPA receptor mediated cell death. A, Bar graph and representative figures
summarizing the glutamate-induced cell death data in the presence/absence of p53 antagonist cyclic PFT-α (10 μM, 1 hr) in HEK-293 T cells
expressing GluR1/2 subunits through quantitative measurements of PI fluorescence. *Significantly different from control group (p < 0.05; n = 9
per group); t-test. B, Bar graph summarizing the glutamate-induced cell death data in the presence/absence of p53 antagonist cyclic PFT-α in
HEK-293 T cells expressing GluR1/3 subunits through quantitative measurements of PI fluorescence (n = 9 per group). C, Bar graph summarizing
the glutamate-induced cell death data obtained from HEK-293 T cells co-expressing GluR1/2 subunits with/without the TAT-GAPDH2–2–1–1
peptide. **Significantly different from non-treatment/transfection group (p < 0.01; n = 9 per group); D. Western blots analysis of GAPDH expression
in the nucleus with/without glutamate treatment in the presence/absence of TAT-GAPDH2–2–1–1 peptide in HEK-293 T cells expressing GluR1/2
subunits. LaminB1 was used as the nuclear marker. E, Western blots analysis of nuclear p53 and p53 phosphorylation at serine46 in HEK-293
T cells co-expressing GluR1/2 subunits with the GAPDH2–2–1–1 mini-gene upon glutamate stimulation. (t-test, *p < 0.05, n = 3).
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in the tMCAo group (326.0 ± 52.73) and scrambled
TAT-GAPDH2–2–1–1 peptide group (291.6 ± 29.77) had
degenerated. However, significantly more neurons
survived in the TAT-GAPDH2–2–1–1 treated group(97.8 ± 10.97, p < 0.001, compared with the tMCAo group
and TAT-GAPDH2–2–1–1-SCRM group). Furthermore, the in-
farct volume is significantly smaller in tMCAo rats treated
with TAT-GAPDH2–2–1–1 peptide (172.8 ± 27.93 mm
3 vs.
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Figure 5 (See legend on next page.)
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Figure 5 TAT-GAPDH2-2-1-1peptide protects tMCAo model from neuronal damage. A, schematic timeline of the transient ischemic stroke
model and treatment. B, representative images of rat brain sections stained with TTC from rats subjected to tMCAo. TAT-GAPDH2-2-1-1 peptide
(40 nmol) was administrated via i.c.v. injection 30 min after the onset of stroke. C, Infarct area of tMCAo rats brain in a series of brain slices according to
the Stereotactic Coordinates in TAT-GAPDH2-2-1-1 and TAT only groups. D, neurological score of tMCAo rats in each group. Neurological score was
assessed both 2 h and 24 h after reperfusion. ANOVA, followed by post-hoc SNK test (*p<0.05). E, Statistic analysis of the tMCAo infarct volume in each
group. The infarct volume of TAT-GAPDH2-2-1-1 group is significantly smaller than that in the TAT only group (172.8±27.93 mm
3 vs. 296.0±41.11 mm3,
n=8 in each group, p<0.05). ANOVA, followed by post-hoc SNK test. F, statistics analysis of tMCAo infarct volume after 1d, 3d and 5d of the
stroke onsets (n=8 per group). G, CoIP of GAPDH by p53 from nuclear proteins in rat cortex of sham, TAT-GAPDH2-2-1-1 and tMCAo only groups
(n=3 per group). ANOVA, followed by post-hoc SNK test. (two sets of experiments are normalized by the tMCAo only group) H, Western blot
analysis of GAPDH nuclear expression in rat cortical tissues from sham, tMCAo, TAT-GAPDH2-2-1-1 (top) and TAT-GAPDH2-2-1-1SCRM (bottom)
groups. The experiments were conducted in two sets. The first set of experiments included three groups: sham, TAT-GAPDH2-2-1-1 and the
tMCAo. The second set of experiments included two groups: the scrambled peptide and the tMCAo group. The bar graph represents each
group normalized with the tMCAo group in the same set of experiments. **Significantly different from sham group (n=3 per group, p<0.01);
##significantly different from tMCAo group (n=3 per group, p<0.01); ANOVA, followed by post-hoc SNK test.
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function is significantly better with TAT-GAPDH2–2–1–1
peptide treatment (Figure 5D). In order to investigate the
neuroprotective effect of this peptide, we have performed
this model for a longer survival period. As shown in
Figure 5F, the protective effect of our peptide can be
observed 5 days post MCAo onset.
To confirm that the observed protective effect of
TAT-GAPDH2–2–1–1 peptide was due to the disruption of
p53-GAPDH interaction and the blockade of GAPDH
nuclear translocation, we measured the p53-GAPDH inter-
action in tMCAo rats with co-immunoprecipitation. As
shown in Figure 5G, the p53-GAPDH interaction is signifi-
cantly increased in the ischemia group compared to the
sham and the TAT-GAPDH2–2–1–1 peptide-treated groups.
This increase was blocked by the TAT-GAPDH2–2–1–1
peptide administered 30 minutes after ischemia via stereo-
taxic i.c.v. injection. Similarly, the nuclear translocation of
GAPDH was also enhanced in the ischemia group and the
ischemia-induced enhancement was inhibited by the appli-
cation of the TAT-GAPDH2–2–1–1 peptide (Figure 5H).
These data together suggest that the p53-GAPDH inter-
action may be involved in the pathophysiology of ischemic
stroke. Disruption of the p53-GAPDH interaction protects
against ischemia-induced neuronal damage and increases
survival after cerebral ischemia.
Discussion
GAPDH nuclear translocation has been implicated in
the pathogenesis of neuronal death [40,50,58,59]. How-
ever, the underlying mechanisms remain unclear. We
have demonstrated in the current study that glutamate
stimulation promotes GAPDH nuclear translocation in a
Siah1-dependent manner. Upon entering the nucleus,
GAPDH forms a complex with p53 and activates the
p53-dependent cell death pathway. We also found an en-
hanced p53-GAPDH interaction in brains of rats sub-
jected to tMCAo. We then used an interfering peptide
to block the p53-GAPDH interaction and reduce braindamage following focal ischemia. These experiments
suggest that the p53-GAPDH interaction plays an im-
portant role in the pathophysiology of ischemic stroke.
GAPDH is overexpressed and accumulates in the nu-
cleus during apoptosis induced by a variety of insults.
Evidence shows that the GAPDH nuclear translocation
is essential for the apoptotic cascade [1,2]. Antisense oli-
gonucleotides that deplete GAPDH prevent this nuclear
translocation and reduce apoptosis [1,3,4]. The mechan-
ism underlying GAPDH nuclear translocation and sub-
sequent cell death remains largely unknown. However,
recent studies have described several factors that may be
involved: (1) the expression of GAPDH is regulated by
p53, a tumor suppressor protein and proapoptotic tran-
scription factor, which suggests that GAPDH could be a
downstream apoptotic mediator [60]; (2) overexpression
of Bcl-2 blocks the apoptotic insults triggered by
GAPDH overexpression, nuclear translocation and sub-
sequent apoptosis, suggesting that Bcl-2 may participate
in the regulation of GAPDH nuclear translocation, con-
sistent with the anti-apoptotic function of Bcl-2 [61]; (3)
GAPDH binds to a nuclear localization signal-containing
protein, Siah1 which initiates GAPDH translocation to the
nucleus. The association with GAPDH stabilizes Siah1
and thereby enhances Siah1-mediated proteolytic cleavage
of its nuclear substrates, triggering apoptosis [4,40,58,62].
We have shown that the knock-down of Siah1 expression
inhibits GAPDH nuclear translocation, providing further
support for the idea that glutamate-induced GAPDH
nuclear translocation is dependent on Siah1.
Consistent with previous studies, our data suggest that
glutamate-induced cell death and ischemic neuronal
damage are associated with the nuclear translocation of
GAPDH and the formation of a p53-GAPDH complex
in the nucleus. Because we observed GAPDH nuclear
translocation in several cell culture types (HEK-293 T ex-
pressing GluR1/2 subunits treated with glutamate, rat hip-
pocampal and cortical primary cultures treated with KA),














Figure 6 Protective effects of the TAT-GAPDH2–2–1–1 peptide
against ischemic neuronal death. A, Images of ischemic ipsilateral
cortex from different treatment group of tMCAo rats were stained with
Fluoro-Jade B 24 h after tMCAo onset. B, Bar graph shows summarized
Fluoro-Jade B labeled cells (n = 5 per group, ***p < 0.001). Data are
mean ± SEM, ANOVA followed by post-hoc SNK test.
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needed to confirm the exact role of p53-GAPDH inter-
action in cell toxicity.
We identified the sequence of GAPDH (I221-E250) that
couples with p53. Hara et al. [4] reported that GAPDH
could exert apoptotic effects through binding to siah-1
for nuclear translocation. They reported the 220–233 re-
gions as the interacting site enabling GAPDH to couple
with Siah1, which is within the GAPDH-p53 interacting
site. Although further experiments are required to iden-
tify the exact amino acid sequences for complex forma-
tion in the two proteins, we speculate that p53 maycompete with Siah1 to bind with GAPDH once the
Siah1-GAPDH complex enters the nucleus. Thus, activa-
tion of AMPA receptor may lead to a sequential protein-
protein interaction that begins with GAPDH-Siah1 com-
plex nuclear translocation followed by the uncoupling of
GAPDH-Siah1 and GAPDH-p53 complex formation that
eventually activates the p53-dependent cell death
pathway.
Almost any DNA-damaging agent can cause apoptosis
of neurons, and this apoptosis is dependent upon p53
[42]. The first indication that p53 is important for neur-
onal damage following ischemia or excitotoxicity came
from studies showing that p53 levels are increased in re-
sponse to these insults [42]. Of particular interest are
studies demonstrating that: (1) neuronal death in the
hippocampal CA1 region was much more extensive in
p53+/+ than in p53−/− mice subjected to transient global
ischemia [63], and (2) transient focal ischemia induced
by tMCAo led to significant ischemic damage in p53+/+
but not in p53+/− mice [64]. The molecular mechanisms
by which p53 is activated and accumulates under condi-
tions of cellular stress may include either phosphoryl-
ation or acetylation of p53 [65].
In our in vivo study, we did not observe a treatment
effect when peptide is administrated 1 h after the stroke
onset (data not shown). This may indicate a limited time
window for the effectiveness of our peptide treatment.
However, this limit may be because of the modeling sys-
tem chosen–we did observed a delayed protective effect
using another peptide on rodent global ischemia model
[36], which seems due to the different modeling system
from the suture insertion tMCAo model. Only when we
observe the delayed treatment effect (administrated 1 h
or later after stroke onset) with our TAT-GAPDH2–2–1–1
peptide in the future experiments, we can confirm the
delayed effect is indeed because of the modeling issue.
Furthermore, intracranial peptide delivery, although at
30 min after termination of suture-insertion surgery,
may affect cerebral blood flow (particularly for the re-
versible MCAO) and/or other factors and thus may have
neuro-protective actions independent of the mechanisms
proposed for the peptide treatment. Although proper
control group is set up, we cannot totally exclude this
confound factor that may affect the outcome of the
peptide treatment. Also, we found a trend of higher
survival of tMCAo rats with TAT-GAPDH2–2–1–1
peptide treatment. Although larger sample size is
required to secure a valid statistical analysis, only ~56%
(9 out of 16) of tMCAo rats survived with the control
peptide, while ~92% (11 out of 12) of tMCAo rats
survived with the TAT-GAPDH2–2–1–1 peptide.
In the present study, the p53 inhibitor PFT-α prevented
glutamate-induced cell death, suggesting the involvement
of p53 in AMPA receptor-mediated cell death. Moreover,
Zhai et al. Molecular Brain 2014, 7:20 Page 11 of 12
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action significantly inhibits glutamate-induced cell death
and ischemia induced neuronal damage. Our data may
provide an opportunity to develop novel therapeutic
agents for the treatment of ischemic stroke.
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